Literature DB >> 7562525

Regulation of allosteric coupling and function of stably expressed gamma-aminobutyric acid (GABA)A receptors by chronic treatment with GABAA and benzodiazepine agonists.

R L Klein1, M P Mascia, P C Harkness, K L Hadingham, P J Whiting, R A Harris.   

Abstract

Chronic treatments with drugs that stimulate or potentiate gamma-aminobutyric acid (GABA)A receptor function cause uncoupling of allosteric sites and downregulation of the GABAA receptors expressed in neurons. To study these effects on receptors having a defined subunit composition, we treated stably transfected mouse Ltk- cells (PA3 cells) with drugs known to uncouple GABAA receptors. Because dexamethasone controls the expression of bovine alpha-1, beta-1 and gamma 2L GABAA receptor subunit genes in PA3 cells, this expression system provides a way to study receptors in the absence of neuronal subunit gene promoters. We assayed binding of [3H]flunitrazepam to measure allosteric coupling and uptake of 36Cl- to measure GABAA receptor function. Chronic (4 day) treatment of PA3 cells with muscimol, GABA or flunitrazepam reduced the GABA enhancement of binding of [3H]flunitrazepam to PA3 cells. Chronic flurazepam or muscimol treatments also caused downregulation of benzodiazepine potentiation of muscimol-stimulated 36Cl- uptake. Chronic treatment with muscimol did not affect levels of subunit mRNAS and alpha 1- or beta 1-subunit protein of GABAA receptors and chronic flunitrazepam did not affect subunit mRNAs or alpha 1 protein. We conclude that chronic drug treatments regulate allosteric coupling and function of GABAA receptors in stably transfected cells and this regulation cannot be attributed to decreases in the expression of receptor subunits or to expression of subunits other than alpha 1 beta 1 or gamma 2L.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7562525

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Allosteric uncoupling and up-regulation of benzodiazepine and GABA recognition sites following chronic diazepam treatment of HEK 293 cells stably transfected with alpha1beta2gamma2S subunits of GABA (A) receptors.

Authors:  Danka Pericić; Dubravka Svob Strac; Maja Jazvinsćak Jembrek; Josipa Vlainić
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-03-22       Impact factor: 3.000

2.  The effects of zolpidem treatment and withdrawal on the in vitro expression of recombinant alpha1beta2gamma2s GABA(A) receptors expressed in HEK 293 cells.

Authors:  Josipa Vlainić; Maja Jazvinsćak Jembrek; Dubravka Svob Strac; Danka Pericić
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-07-23       Impact factor: 3.000

3.  Relative potency and effectiveness of flunitrazepam, ethanol, and beta-CCE for disrupting the acquisition and retention of response sequences in rats.

Authors:  Stuart T Leonard; Lisa R Gerak; Marcus S Delatte; Joseph M Moerschbaecher; Peter J Winsauer
Journal:  Behav Pharmacol       Date:  2009-02       Impact factor: 2.293

4.  Differential effects of short- and long-term zolpidem treatment on recombinant α1β2γ2s subtype of GABA(A) receptors in vitro.

Authors:  Josipa Vlainić; Maja Jazvinšćak Jembrek; Toni Vlainić; Dubravka Švob Strac; Danka Peričić
Journal:  Acta Pharmacol Sin       Date:  2012-08-27       Impact factor: 6.150

5.  Pharmacological plasticity of GABA(A) receptors at dentate gyrus synapses in a rat model of temporal lobe epilepsy.

Authors:  Claire Leroy; Pierrick Poisbeau; A Florence Keller; Astrid Nehlig
Journal:  J Physiol       Date:  2004-03-19       Impact factor: 5.182

6.  Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective GABA(A) Receptor Modulators?

Authors:  Christiaan H Vinkers; Berend Olivier
Journal:  Adv Pharmacol Sci       Date:  2012-03-29

Review 7.  Valium without dependence? Individual GABAA receptor subtype contribution toward benzodiazepine addiction, tolerance, and therapeutic effects.

Authors:  Tianze Cheng; Dominique Marie Wallace; Benjamin Ponteri; Mahir Tuli
Journal:  Neuropsychiatr Dis Treat       Date:  2018-05-23       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.